70822-02-5

Upstream product

• 64-17-5 ethanol 
• 59212-11-2 2-(3,4-dimethoxyphenyl)-2-methylpropanoic acid 
• 23023-16-7 2‐(3,4‐dimethoxyphenyl)‐2‐methylpropionitrile 
• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 74-88-4 methyl iodide 

Downstream Products

• 1239964-44-3 2-(3,4-dimethoxyphenyl)-2-methylpropanehydrazide 
• 1239956-62-7 3-(2-chloro-6-fluorobenzylthio)-5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-4-(4-fluorophenyl)-4H-1,2,4-triazole 
• 1239964-46-5 3-(2-(3,4-dimethoxyphenyl)propan-2-yl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5(4H)-thione 
• 70822-01-4 2-(3,4-dimethoxy-phenyl)-2-methyl-propan-1-ol 

Relevant academic research and scientific papers

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE DERIVATIVES

A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.